23.99  0.01 (0.04%)		12-05 16:00
Open: 23.99 High: 24 Volume: 7,430,229		Pre. Close: 23.98 Low: 23.98 Market Cap: 5,521(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Abcam plc operates as a prominent life science enterprise, dedicated to the innovation, creation, and supply of crucial reagents and instruments. These fundamental resources are instrumental in supporting diverse scientific investigations, diagnostic applications, and the advancement of pharmaceutical drug discovery initiatives. Its comprehensive product portfolio features primary and secondary antibodies, conjugated antibodies paired with their respective kits, both singleplex and multiplex immunoassays, as well as a variety of proteins and peptides, including cytokines. Furthermore, the company provides edited cell lines, lysates, cellular activity kits, miRNA kits, biochemical compounds, and specialized tools for analyzing cell signaling pathways. Abcam serves a broad customer base, encompassing researchers and scientists within academic and institutional environments, alongside professionals at pharmaceutical, biotechnology, and diagnostic companies. The company boasts a global presence, conducting operations across the Americas, Europe, the Middle East, Africa, China, Japan, and the wider Asia Pacific region. Product distribution is primarily facilitated via its online platform. Founded in 1998, Abcam plc is headquartered in Cambridge, United Kingdom.

Fri, 04 Apr 2025
Publication of 2022 annual report & accounts, notice of annual general meeting - Abcam

Mon, 16 Oct 2023
Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short - Proactive Investors

Mon, 28 Aug 2023
Danaher to acquire Abcam for $24.00 per share - Abcam

Mon, 28 Aug 2023
Danaher reaches $5.7B deal to acquire Abcam - The Business Journals

Mon, 28 Aug 2023
Danaher Buys Abcam for $5.7 Billion to Expand Its Product Offerings - Investopedia

Fri, 30 Jun 2023
Abcam plc Interim Results for the Six-Month Period Ended 30 June 2023 - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date